32,212 results match your criteria Radiation Therapy Prostate Cancer


Effects of a multicomponent resistance-based exercise program with protein, vitamin D and calcium supplementation on cognition in men with prostate cancer treated with ADT: secondary analysis of a 12-month randomised controlled trial.

BMJ Open 2022 Jun 24;12(6):e060189. Epub 2022 Jun 24.

Institute for Physical Activity and Nutrition (IPAN), School of Exercise and Nutrition Sciences, Deakin University, Geelong, Victoria, Australia.

Objectives: The aim of this preplanned secondary analysis of a 12-month randomised controlled trial was to investigate the effects of a multicomponent exercise programme combined with daily whey protein, calcium and vitamin D supplementation on cognition in men with prostate cancer treated with androgen deprivation therapy (ADT).

Design: 12-month, two-arm, randomised controlled trial.

Setting: University clinical exercise centre. Read More

View Article and Full-Text PDF

Risk Factors for Biochemical Recurrence After PSMA-PET-Guided Definitive Radiotherapy in Patients With Lymph Node-Positive Prostate Cancer.

Front Oncol 2022 7;12:898774. Epub 2022 Jun 7.

Department of Radiation Oncology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.

Introduction: The National Comprehensive Cancer Network recommends external beam radiotherapy (EBRT) combined with androgen deprivation therapy (ADT) as the preferred treatment option for newly diagnosed node-positive (cN1) prostate cancer (PCa) patients. However, implementation of positron emission tomography targeting prostate-specific membrane antigen (PSMA-PET) in the staging of primary PCa patients has a significant impact on RT treatment concepts. This study aims to evaluate outcomes and their respective risk factors on patients with PSMA-PET-based cN1 and/or cM1a PCa receiving primary RT and ADT. Read More

View Article and Full-Text PDF

Longitudinal Correlations Between Intravoxel Incoherent Motion (IVIM) and Dynamic Contrast-Enhanced (DCE) MRI During Radiotherapy in Prostate Cancer Patients.

Front Oncol 2022 7;12:897130. Epub 2022 Jun 7.

Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, Netherlands.

Purpose: Intravoxel incoherent motion (IVIM) is a promising technique that can acquire perfusion information without the use of contrast agent, contrary to the more established dynamic contrast-enhanced (DCE) technique. This is of interest for treatment response monitoring, where patients can be imaged on each treatment fraction. In this study, longitudinal correlations between IVIM- and DCE parameters were assessed in prostate cancer patients receiving radiation treatment. Read More

View Article and Full-Text PDF

COVID-19 vaccination simulating lymph node progression in a patient with prostate cancer.

Radiol Case Rep 2022 Sep 17;17(9):2996-2999. Epub 2022 Jun 17.

Unit of Diagnostic Imaging and Interventional Radiology, Fondazione Policlinico Campus Bio-Medico di Roma, Università Campus Bio-Medico di Roma, via Alvaro del Portillo 21, Rome 00128, Italy.

Several cases of cancer patients with 18-fluorodeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) evidence of metabolically active axillary lymph nodes after COVID-19 vaccination have been described, creating a diagnostic dilemma and sometimes leading to further unnecessary examinations. A 62-year-old male, diagnosed with prostate cancer, treated with hormone-therapy and radiotherapy of the prostate 2 years before, underwent fluorine-18 choline (F-FCH) PET/CT for restaging purpose, less than 3 weeks after he had received the second dose of the Pfizer BioNTech-BNT162b2 mRNA COVID-19 vaccine. This exam showed an increased F-FCH uptake and an enlargement of the left axillary, paratracheal, para-aortic, subcarinal, and hilar bilateral lymph nodes. Read More

View Article and Full-Text PDF
September 2022

The SAFE Pilot Trial-SAlvage Focal Irreversible Electroporation-For Recurrent Localized Prostate Cancer: Rationale and Study Protocol.

Front Surg 2022 7;9:900528. Epub 2022 Jun 7.

Department of Surgical Sciences and Urology Clinic, University of Turin and Città della Salute e della Scienza, Turin, Italy.

Introduction: Currently, the majority of prostate cancer (PCa) recurrences after non-surgical first-line treatment are managed with androgen-deprivation therapy (ADT). Salvage radical prostatectomy (sRP) is a curative alternative to ADT but yields significant morbidity. Preliminary evidence from focal salvage treatments shows similar oncological control but lower morbidity compared to sRP. Read More

View Article and Full-Text PDF

Copper-67-Labeled Bombesin Peptide for Targeted Radionuclide Therapy of Prostate Cancer.

Pharmaceuticals (Basel) 2022 Jun 8;15(6). Epub 2022 Jun 8.

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO 63108, USA.

The gastrin-releasing peptide receptor (GRPR) is a promising molecular target for imaging and therapy of prostate cancer using bombesin peptides that bind to the receptor with high affinity. Targeted copper theranostics (TCTs) using copper radionuclides, Cu for imaging and Cu for therapy, offer significant advantages in the development of next-generation theranostics. [Cu]Cu-SAR-BBN is in clinical development for PET imaging of GRPR-expressing cancers. Read More

View Article and Full-Text PDF

Could 68Ga-PSMA PET/CT Evaluation Reduce the Number of Scheduled Prostate Biopsies in Men Enrolled in Active Surveillance Protocols?

J Clin Med 2022 Jun 16;11(12). Epub 2022 Jun 16.

Urology Unit, Cannizzaro Hospital, 95126 Catania, Italy.

Background: To evaluate the accuracy of 68Ga-prostate specific membrane antigen (PSMA) PET/CT in the diagnosis of clinically significant prostate cancer (csPCa) (Grade Group > 2) in men enrolled in Active Surveillance (AS) protocol.

Methods: From May 2013 to May 2021, 173 men with very low-risk PCa were enrolled in an AS protocol study. During the follow-up, 38/173 (22%) men were upgraded and 8/173 (4. Read More

View Article and Full-Text PDF

The Latest Data Specifically Focused on Long-Term Oncologic Prognostication for Very Old Adults with Acute Vulnerable Localized Prostate Cancer: A Nationwide Cohort Study.

J Clin Med 2022 Jun 15;11(12). Epub 2022 Jun 15.

Biotech and Healthcare Management, School of Health Care Administration, College of Management, Taipei Medical University, Taipei 110, Taiwan.

Purpose: Few studies have evaluated the prime treatment choice for men older than 80 years with acute vulnerable localized prostate cancer (AV-LPC). Clinicians have been deeply troubled by this near end-of-life medical choice for a very specific group of patients. We compared the oncological prognostication of very old patients with AV-LPC after they underwent either radical prostatectomy (RP) or massive-dose intensity-modulated radiotherapy (IMRT) coupled with long-term androgen deprivation therapy (ADT) over a long-term investigation. Read More

View Article and Full-Text PDF

The RelB-BLNK Axis Determines Cellular Response to a Novel Redox-Active Agent Betamethasone during Radiation Therapy in Prostate Cancer.

Int J Mol Sci 2022 Jun 8;23(12). Epub 2022 Jun 8.

Department of Toxicology and Cancer Biology, University of Kentucky, 452 Health Sciences Research Building, Lexington, KY 40536, USA.

Aberrant levels of reactive oxygen species (ROS) are potential mechanisms that contribute to both cancer therapy efficacy and the side effects of cancer treatment. Upregulation of the non-canonical redox-sensitive NF-kB family member, RelB, confers radioresistance in prostate cancer (PCa). We screened FDA-approved compounds and identified betamethasone (BET) as a drug that increases hydrogen peroxide levels in vitro and protects non-PCa tissues/cells while also enhancing radiation killing of PCa tissues/cells, both in vitro and in vivo. Read More

View Article and Full-Text PDF

Prostate Cancer Diagnosis, Treatment and Outcomes in Patients with Previous or Synchronous Colorectal Cancer: A Systematic Review of Published Evidence.

Diagnostics (Basel) 2022 Jun 15;12(6). Epub 2022 Jun 15.

Department of Neurosciences, Reproductive Sciences and Odontostomatology, University of Naples Federico II, 80130 Naples, Italy.

The management of patients with prostate cancer (PCa) and previous or synchronous colorectal cancer (CRC) represents a challenging issue. A systematic review was performed in May 2022 to summarize available evidence about the diagnosis, management, and outcomes of these patients. Twenty-seven studies involving 252 patients were identified. Read More

View Article and Full-Text PDF

Predictors of Bone Metastases at Ga-PSMA-11 PET/CT in Hormone-Sensitive Prostate Cancer (HSPC) Patients with Early Biochemical Recurrence or Persistence.

Diagnostics (Basel) 2022 May 24;12(6). Epub 2022 May 24.

Nuclear Medicine, Department of Medical Sciences, AOU Città Della Salute e Della Scienza di Torino, University of Turin, 10126 Turin, Italy.

Prostate-specific-membrane-antigen/positron-emission-tomography (PSMA-PET) can accurately detect disease localizations in prostate cancer (PCa) patients with early biochemical recurrence/persistence (BCR/BCP), allowing for more personalized image-guided treatments in oligometastatic patients with major impact in the case of bone metastases (BM). Therefore, this study aimed to identify predictors of BM at PSMA-PET in early-BCR/BCP hormone-sensitive PCa (HSPC) patients, previously treated with radical intent (radiotherapy or radical prostatectomy ± salvage-radiotherapy (SRT)). A retrospective analysis was performed on 443 Ga-PSMA-11-PET/CT scans. Read More

View Article and Full-Text PDF

Role of Brachytherapy Boost in Clinically Localized Intermediate and High-Risk Prostate Cancer: Lack of Benefit in Patients with Very High-Risk Factors T3b-4 and/or Gleason 9-10.

Cancers (Basel) 2022 Jun 16;14(12). Epub 2022 Jun 16.

Department of Radiology, Ujitakeda Hospital, Uji-City, Kyoto 611-0021, Japan.

This study examined the role of brachytherapy boost (BT-boost) and external beam radiotherapy (EBRT) in intermediate- to high-risk prostate cancer, especially in patients with very high-risk factors (VHR: T3b-4 or Gleason score 9-10) as patients with double very high-risk factors (VHR-2: T3b-4 and Gleason score 9-10) previously showed worst prognosis in localized prostate cancer. We retrospectively reviewed multi-institutional data of 1961 patients that were administered radiotherapy (1091 BT-boost and 872 EBRT: 593 conventional-dose RT (Conv RT: equivalent to doses of 2 Gy per fraction = EQD2 ≤ 72 Gy) and 216 dose-escalating RT (DeRT = EQD2 ≥ 74 Gy). We found that BT-boost improved PSA control and provided an equivalent overall survival rate in the intermediate- and high-risk groups, except for patients within the VHR factor group. Read More

View Article and Full-Text PDF

Phase II Trial of Sipuleucel-T and Stereotactic Ablative Body Radiation for Patients with Metastatic Castrate-Resistant Prostate Cancer.

Biomedicines 2022 Jun 15;10(6). Epub 2022 Jun 15.

Department of Medical Oncology, UT Southwestern Medical Center, Dallas, TX 75390, USA.

(1) We hypothesized that adding concurrent stereotactic ablative radiotherapy (SAbR) would increase the time to progression in patients with metastatic castrate-resistant prostate cancer (mCRPCA) treated with sipuleucel-T. (2) Patients with a history of prostate cancer (PC), radiographic evidence of metastatic disease, and rising prostate-specific antigen (PSA) > 0.2 ng/dL on castrate testosterone levels were enrolled in this single-arm phase II clinical trial and treated with sipuleucel-T and SAbR. Read More

View Article and Full-Text PDF

The Usefulness of Adaptative Radiotherapy in Prostate Cancer: How, When, and Who?

Biomedicines 2022 Jun 13;10(6). Epub 2022 Jun 13.

Department of Radiation Oncology, Hospital Provincial de Castellón, Avda. Dr Clará 19, 12002 Castellón de la Plana, Spain.

The aim of this study was to develop a deformable image registration (DIR)-based offline ART protocol capable of identifying significant dosimetric changes in the first treatment fractions to determine when adaptive replanning is needed. A total of 240 images (24 planning CT (pCT) and 216 kilovoltage cone-beam CT (CBCT)) were prospectively acquired from 24 patients with prostate adenocarcinoma during the first three weeks of their treatment (76 Gy in 38 fractions). This set of images was used to plan a hypofractionated virtual treatment (57. Read More

View Article and Full-Text PDF

Stratification of Oligometastatic Prostate Cancer Patients by Liquid Biopsy: Clinical Insights from a Pilot Study.

Biomedicines 2022 Jun 4;10(6). Epub 2022 Jun 4.

Department of Radiation Oncology, University and Spedali Civili Hospital, 25123 Brescia, Italy.

We propose a pilot, prospective, translational study with the aim of identifying possible molecular markers underlying metastatic prostate cancer (PC) evolution with the use of liquid biopsy. Twenty-eight castrate sensitive, oligometastatic PC patients undergoing bone and/or nodal stereotactic body radiotherapy (SBRT) were recruited. Peripheral blood samples were collected before the commencement of SBRT, then they were processed for circulating cell free DNA (cfDNA) extraction. Read More

View Article and Full-Text PDF

Long-term urological complications after conservative local treatment (surgery and brachytherapy) in children with bladder-prostate rhabdomyosarcoma: A single-team experience.

Pediatr Blood Cancer 2022 Aug 6;69(8):e29532. Epub 2022 Jan 6.

Department of Pediatric Surgery, Bicêtre Hospital, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Le Kremlin-Bicêtre, France.

Background: Outcome of children with bladder-prostate rhabdomyosarcoma (RMS) has improved with multimodal therapies, including surgery and/or radiotherapy for local treatment. Our aim was to report long-term urological complications after a conservative approach combining conservative surgery and brachytherapy.

Patients And Methods: Eighty-six patients, free of disease, were retrospectively reviewed. Read More

View Article and Full-Text PDF

The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).

J Nucl Med 2022 Jun 23. Epub 2022 Jun 23.

Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Australia.

Lutetium PSMA-617 (LuPSMA-617) therapy has shown high prostate specific antigen (PSA) response rates in men with metastatic castration-resistant prostate cancer (mCRPC). However early treatment resistance is common. This LUPIN sub-study aimed to determine the prognostic value of post-treatment quantitative PET for PSA progression free (PSA-PFS) and overall survival (OS) with LuPSMA-617 therapy. Read More

View Article and Full-Text PDF

Cranial Radiotherapy for Prostate Cancer Patients With Brain Metastases Inaccessible to Stereotactic Radiotherapy.

In Vivo 2022 Jul-Aug;36(4):1841-1846

Institute for Radiation Oncology, Cantonal Hospital Winterthur, Winterthur, Switzerland.

Background/aim: To evaluate patients and treatment characteristics as well as clinical outcome in patients with intracranial metastases from prostate cancer (PCA) treated with palliative radiotherapy.

Patients And Methods: Fifteen patients treated for intracranial metastases of PCA were identified. The median age of patients was 69 years. Read More

View Article and Full-Text PDF

Acute and Late Rectal Toxicity Following Hypofractionated Radiotherapy in Patients With Prostate Cancer: Results of a Prospective Study.

In Vivo 2022 Jul-Aug;36(4):1875-1880

Oncology Unit, 3 Department of Internal Medicine, Sotiria Athens General Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece;

Background/aim: Previous randomized clinical trials have shown that moderate hypofractionation has a non-inferior or even superior efficacy to conventionally fractionated external beam radiation therapy (EBRT) in low and intermediate-risk prostate cancer. We herein aimed to evaluate the acute and late gastrointestinal (GI) toxicity of hypofractionated radiotherapy (HRT) in a real-world setting.

Patients And Methods: Patients with intermediate-risk prostate adenocarcinoma eligible to receive HRT were prospectively enrolled. Read More

View Article and Full-Text PDF

Error Detectability of Isodose Volumes as ROIs in Prostate Intensity-modulated RT QA.

In Vivo 2022 Jul-Aug;36(4):1887-1895

Department of Radiology, Hyogo Medical University, Nishinomiya, Japan.

Background/aim: To evaluate the quality of error detectability with a three-dimensional verification system using isodose volumes as regions of interest (ROIs) in quality assurance (QA) of intensity-modulated radiation therapy.

Patients And Methods: Treatment plans with four types of intentional errors were created from the data of 20 patients with localized prostate cancer. These plans underwent QA using the three-dimensional verification system. Read More

View Article and Full-Text PDF

Completeness of reporting oligometastatic disease characteristics in literature and influence on oligometastatic disease classification using the ESTRO/EORTC nomenclature.

Int J Radiat Oncol Biol Phys 2022 Jun 20. Epub 2022 Jun 20.

University Hospital Zurich, University of Zurich, Department of Radiation Oncology, Zurich, Switzerland.

Background: There is increasing evidence for the integration of locally ablative therapy into multimodality treatment of oligometastatic disease (OMD). To support standardised data collection, analysis, and comparison, a consensus OMD classification based on fundamental disease and treatment characteristics has previously been established. This study investigated the completeness of reporting the proposed OMD characteristics in literature and evaluated whether the proposed OMD classification system can be applied to the historical data. Read More

View Article and Full-Text PDF

Biochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601.

J Clin Oncol 2022 Jun 23:JCO2102741. Epub 2022 Jun 23.

Department of Radiation Oncology, University Hospitals, Cleveland, OH.

Purpose: Metastasis-free survival (MFS), but not event-free survival, is a validated surrogate end point for overall survival (OS) in men treated for localized prostate cancer. It remains unknown if this holds true in biochemically recurrent disease after radical prostatectomy. Leveraging NRG/RTOG 9601, we aimed to determine the performance of intermediate clinical end points (ICEs) as surrogate end points for OS in recurrent prostate cancer. Read More

View Article and Full-Text PDF

Web-Based Peer Navigation for Men with Prostate Cancer and Their Family Caregivers: A Pilot Feasibility Study.

Curr Oncol 2022 Jun 15;29(6):4285-4299. Epub 2022 Jun 15.

Division of Health Services and Policy, School of Population and Public Health, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.

This study assessed the feasibility, acceptability and potential effects of True North Peer Navigation (PN)-a web-based peer navigation program for men with prostate cancer (PC) and their family caregivers. A one-arm, pre-post pilot feasibility study was conducted at two cancer centres in Canada. Participants were matched through a web-app with a specially trained peer navigator who assessed needs and barriers to care, provided support and encouraged a proactive approach to health for 3 months. Read More

View Article and Full-Text PDF

Prostate cancer: understanding patients' treatment options.

Authors:
Andrew Hart

Nurs Stand 2022 Jun 23. Epub 2022 Jun 23.

uro-oncology, Worthing Hospital, Worthing, England.

Prostate cancer is the most common cancer among men in the UK. It is a disease with no specific preventable risk factors, no specific signs and symptoms, and a significant health burden. This article explains the various treatment options available for patients with prostate cancer, with the aim of assisting nurses in supporting person-centred decision-making. Read More

View Article and Full-Text PDF

Germline Mutations in Patients With Early-Onset Prostate Cancer.

Front Oncol 2022 6;12:826778. Epub 2022 Jun 6.

Department of Urology, Daping Hospital, Army Medical University, Chongqing, China.

Objective: To investigate the inherited mutations and their association with clinical features and treatment response in young-onset prostate cancer patients.

Method: Targeted gene sequencing on 139 tumor susceptibility genes was conducted with a total of 24 patients diagnosed with PCa under the age of 63 years old. Meanwhile, the related clinical information of those patients is collected and analyzed. Read More

View Article and Full-Text PDF

Clinical rationale for portal dosimetry in magnetic resonance guided online adaptive radiotherapy.

Phys Imaging Radiat Oncol 2022 Jul 11;23:16-23. Epub 2022 Jun 11.

Department of Radiation Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands.

Background And Purpose: In magnetic resonance guided online adaptive radiotherapy, the patient model used for plan adaptation and dose calculation is created online under stringent time constraints. This study investigated the ability of portal dosimetry to detect deviations between the online patient model used for plan adaptation and the actual anatomy of the patient during delivery.

Materials And Methods: Portal images acquired during treatment were used to reconstruct the delivered dose corresponding to online adapted plans of 42 prostate and 20 rectal cancer patients. Read More

View Article and Full-Text PDF

Update on cancer therapy-induced atherosclerosis.

Curr Opin Cardiol 2022 Jul;37(4):372-379

Franciscan CardioOncology Center, IC-OS Center of Excellence, Indiana Heart Physicians, Franciscan Health, Indianapolis, Indiana, USA.

Purpose Of Review: Recent advances in oncologic therapies have significantly improved overall survival for patients with malignancy. However, cardiovascular complications have not only increased in this population due to shared risk factors and pathophysiology, but also due to the therapies themselves. One key mechanism that warrants further attention is accelerated atherosclerosis due to these agents. Read More

View Article and Full-Text PDF

Contemporary trends in the surgical management of urinary incontinence after radical prostatectomy in the United States.

Prostate Cancer Prostatic Dis 2022 Jun 21. Epub 2022 Jun 21.

Department of Urology, Stanford University School of Medicine, Stanford, CA, USA.

Purpose: To identify trends, costs, and predictors in the use of different surgical procedures for post-radical prostatectomy incontinence (PPI).

Materials And Methods: We identified 21,589 men who were diagnosed with localized prostate cancer (PCa) and treated with radical prostatectomy (RP) from 2003 to 2017. The primary outcome was the incontinence procedure performances. Read More

View Article and Full-Text PDF

After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a population-based analysis.

Brachytherapy 2022 Jun 18. Epub 2022 Jun 18.

Department of Radiation Oncology, British Columbia Cancer Agency Vancouver Centre, Vancouver, British Columbia, Canada; Department of Surgery, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.

Purpose: To evaluate the outcomes of unfavorable intermediate-risk (UIR) and high-risk (HR) prostate cancer patients treated with combined external beam radiation therapy (EBRT) and low-dose-rate prostate brachytherapy (LDR-PB).

Methods And Materials: A population-based cohort of 568 prostate cancer patients treated with combined EBRT and LDR-PB from 2010 to 2016 was analyzed. All patients received EBRT followed by LDR-PB boost. Read More

View Article and Full-Text PDF

Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline.

J Clin Oncol 2022 Jun 21:JCO2200868. Epub 2022 Jun 21.

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ.

Purpose: To provide recommendations for the management of patients with metastatic clear cell renal cell carcinoma (ccRCC).

Methods: An Expert Panel conducted a systematic literature review to obtain evidence to guide treatment recommendations.

Results: The panel considered peer-reviewed reports published in English. Read More

View Article and Full-Text PDF